Physician profile
Michelle Mcbride
NPI 1699291534
$29,155.93
in general payments reported to CMS, 2019-2025
23 companies · $5,640 in 2025
The $5,640 reported for 2025 was more than what 99% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,497 · 2022: $6,432 · 2023: $8,413 · 2024: $5,175 · 2025: $5,640.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $12K · Food and Beverage: $6,866 · Travel and Lodging: $220 · Education: $17.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $12,125.00 |
| Food and Beverage | $6,865.92 |
| Travel and Lodging | $219.56 |
| Education | $17.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $20,711.30 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $1,675.73 | 2021-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Otsuka America Pharmaceutical, INC. | $1,288.74 | 2021-2025 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Alkermes, INC. | $1,200.88 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Lundbeck LLC | $720.61 | 2021-2025 | Rexulti, Abilify Maintena |
| Supernus Pharmaceuticals, INC. | $652.57 | 2021-2025 | Qelbree, Qelbree |
| Neurocrine Biosciences, INC. | $589.71 | 2021-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $551.68 | 2022-2025 | Austedo Xr, Austedo Xr, Austedo |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $364.93 | 2021-2025 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $306.93 | 2024-2025 | Cobenfy |
| Sunovion Pharmaceuticals INC. | $249.32 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $180.44 | 2024-2025 | Hetlioz, Fanapt |
| Axsome Therapeutics, INC. | $163.37 | 2022-2025 | Auvelity |
| Idorsia Pharmaceuticals US INC | $142.08 | 2023 | Quviviq |
| Indivior INC. | $95.45 | 2022-2023 | Perseris |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $73.07 | 2022-2025 | Trintellix |
| Merck Sharp & Dohme LLC | $46.12 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $34.92 | 2024-2025 | |
| Corium, LLC | $34.27 | 2022 | |
| Almatica Pharma LLC | $19.88 | 2025 | Loreev Xr |
| Alcresta Therapeutics, INC. | $18.77 | 2024 | Relizorb |
| Glaxosmithkline, LLC. | $18.47 | 2024 | Nucala |
| Neos Therapeutics, LP | $16.69 | 2025 | Adzenys Xr-Odt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Mcbride listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.